>> Key to making the process work in people is finding the right homing device to direct TF to a tumor's blood vessels. Thorpe already has engineered drugs that would target one substance, called vascular endothelial cell growth factor. A biotechnology firm, Techniclone Corp. of Tustine, Calif., is licensing the therapy and plans to begin testing it in people within two years.
Just remember what the original Techniclone Corp. licensed bavituximab for, engineered drugs that would target one substance, called vascular endothelial cell growth factor (VEGF)!
Market Data 
Markets 
AI
